Thus, it is possible that our dyslipidemic individuals may have low innate IL-10 production capacity, which fails to limit the chronic pro-inflammatory state characteristic of MetS, with the subsequent observed dyslipidemic effects. This evidence concerns the gene IL10 and metabolic syndrome.